高频振荡通气联合西地那非治疗新生儿持续性肺动脉高压

目的探讨高频振荡通气(HFOV)联合西地那非治疗新生儿持续性肺动脉高压(PPHN)的疗效。方法 50例PPHN患儿分为HFOV组(A组,n=16)、HFOV联合低剂量西地那非组(B组,n=16)和HFOV联合高剂量西地那非组(C组,n=18),观察并比较3组治疗前及治疗3 d后肺动脉压(PAP)、动脉血氧分压(PaO2)、动脉血氧饱和度(SaO2)和动脉血CO2分压(PaCO2)。结果治疗前各组PAP、PaO2、SaO2及PaCO2比较差异均无统计学意义(P>0.05)。治疗后各组PAP较治疗前均显著下降,差异有统计学意义(P<0.05);各组PAP降幅比较差异均有统计学意义(P<0.05)。C组治疗有效率高于A组,差异有统计学意义(P<0.05)。治疗后各组PaO2、SaO2较治疗前升高,PaCO2下降,差异均有统计学意义(P<0.05)。B、C 2组PaO2和SaO2升高的幅度及PaCO2下降的幅度大于A组,差异有统计学意义(P<0.05)。C组SaO2升高的幅度和PaCO2下降的幅度大于B组,差异有统计学意义(P<0.05)。结论 HFOV联合西地那非治疗PPHN疗效较好。

High frequency oscillatory ventilation combined with sidenafil for treatment on persistent pulmonary hypertension of the newborn

Objective To investigate the curative effect of high frequency oscillatory ventilation （HFOV） combined with sidenafil for treatment on persistent pulmonary hypertension of the newborn（PPHN）. Methods Fifty PPHN patients were divided into HFOV group（ group A,n = 16）,HFOV combined with low-dose sidenafil group（ group B ,n = 16） and HFOV combined with high-dose sidenafil group（ group C, n = 18 ）. The pulmonary artery pressure（ PAP）, arterial oxygen tension（ PaO2 ）, arterial oxygen saturation（ SaOz ） and arterial carbon dioxide tension（ PaCO2 ） of the three groups were observed before treatment and three days after treatment and then were analysed. Results Before treatment, there was no statistic significance of PaO2, SaO2 and PaCO2 among the groups （P 〉 0.05）. Compared with before treatment, the PAP after treatment was decreased （ P 〈 0.05 ） and the differences before and after treatment among the three groups were statistic（ P 〈 0.05 ）. Compared with before treatment, the PaO2 and SaO2 increased, and the PaCO2 decreased after treatment （ P 〈 0.05 ） ; and the differences of PaO2, SaO2 and PaCO2 before and after treatment in group B and C were greater than those in group A （P 〈 0.05 ） ;the differences of SaO2 and PaCO2 before and after treatment in group C were greater than those in group B （P 〈 0.05 ）. Conclusion The HFOV combined with sidenafil for treatment on PPHN has satisfactory efficacy.